RxDoctor Payments Data

Shobin Oommen, MD

Psychiatry · Stroudsburg, PANPI 1205035383

Payments from drug & device makers

$1,185in general payments, 2019–2025

Across 17 payments — averaging $69.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$675
  • Acadia Pharmaceuticals Inc$214
  • Avanir Pharmaceuticals, Inc.$121
  • Neurocrine Biosciences, Inc.$105
  • Collegium Pharmaceutical, Inc.$24
  • Johnson & Johnson$23
  • plus $22 from 1 others

What the payments were for

  • Food & beverage$1,185100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,185 in reported general payments places this provider in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$549,215
Medicare patients
529
Services billed
4,486

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AristadaAripiprazole Lauroxil82$295,124
Invega SustennaPaliperidone Palmitate62$187,762
Abilify MaintenaAripiprazole48$144,154
Risperdal ConstaRisperidone Microspheres96$129,440
Risperidone ErRisperidone Microspheres44$43,455
Fluphenazine Hcl168$43,400
Olanzapine OdtOlanzapine143$38,085
Aripiprazole411$30,558
Risperidone OdtRisperidone94$28,968
Clozapine OdtClozapine43$27,733
Clozapine318$22,560
Divalproex Sodium596$21,591
Haloperidol573$20,946
Divalproex Sodium ErDivalproex Sodium183$17,311
Clomipramine Hcl41$14,080

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$23$317,202158 claims
Alkermes, Inc.Aristada$675$295,12482 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$22$144,15448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Stroudsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →